ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well ABI-007 works in treating patients with persistent
or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.